Chemours Announces Proposed Private Offering of $750 Million Aggregate Principal Amount of Senior Unsecured Notes

PR Newswire

WILMINGTON, Del., Nov. 12, 2020 /PRNewswire/ — The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company with leading market positions in Fluoroproducts, Chemical Solutions and Titanium Technologies, today announced that it intends to offer, subject to market and other conditions, $750 million in aggregate principal amount of fixed rate senior notes in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The notes will be Chemours’ senior unsecured obligations and will be guaranteed by certain of its subsidiaries.

The net proceeds of the offering are expected to be used, together with cash on hand, (i) to fund the purchase price and accrued and unpaid interest for any and all of Chemours’ outstanding 6.625% senior notes due 2023 (the “existing 2023 notes”) validly tendered and accepted for payment pursuant to Chemours’ previously announced cash tender offer for any and all of the existing 2023 notes (the “Tender Offer”) and (ii) to the extent applicable, to fund the redemption price and accrued and unpaid interest for any existing 2023 notes that remain outstanding after the completion or termination of the Tender Offer.

The notes and the related guarantees have not been, and will not be, registered under the Securities Act or any state securities laws, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.  The notes are being offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and to non-U.S. persons in accordance with Regulation S under the Securities Act. 

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is not an offer to purchase or the solicitation of an offer to sell any of the existing 2023 notes. The Tender Offer referenced herein is being made only by and pursuant to the terms of the applicable Offer to Purchase and Consent Solicitation Statement. The statements in this press release with respect to the redemption of the existing 2023 notes do not constitute a notice of redemption under the indenture governing the existing 2023 notes. Any such notice has or will be sent to holders of existing 2023 notes only in accordance with the provisions of such indenture.

About The Chemours Company


The Chemours Company (NYSE: CC) is a global leader in Titanium Technologies, Fluoroproducts, and Chemical Solutions, providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations.  Chemours ingredients are found in plastics and coatings, refrigeration and air conditioning, mining, and general industrial manufacturing. Our flagship products include prominent brands such as Teflon™, Ti-Pure™, Krytox™, Viton™, Opteon™, Freon™ and Nafion™. In 2019, Chemours was named to Newsweek’s list of America’s Most Responsible Companies. The company has approximately 7,000 employees and 30 manufacturing sites serving approximately 3,700 customers in over 120 countries. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC.

Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words “believe,” “expect,” “will,” “anticipate,” “plan,” “estimate,” “target,” “project” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance, business plans, prospects, targets, goals and commitments, capital investments and projects, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours’ control. In addition, the current COVID-19 pandemic has significantly impacted the national and global economy and commodity and financial markets. The full extent and impact of the pandemic is unknown and to date has included extreme volatility in financial and commodity markets, a significant slowdown in economic activity, and increased predictions of a global recession. The public and private sector response has led to significant restrictions on travel, temporary business closures, quarantines, stock market volatility, and a general reduction in consumer and commercial activity globally. Matters outside our control have affected our business and operations and may or may continue to limit travel of employees to our business units domestically and internationally, adversely affect the health and welfare of our personnel, significantly reduce the demand for our products, hinder our ability to provide goods and services to customers, cause disruptions in our supply chains, adversely affect our business partners or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include, but are not limited to: the terms and timing of the offering, the Tender Offer and any redemptions of the existing 2023 notes; and the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020 and our Annual Report on Form 10-K for the year ended December 31, 2019. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

CONTACT:

INVESTORS 
Jonathan Lock 
VP, Corporate Development and Investor Relations 
+1.302.773.2263 
[email protected] 

NEWS MEDIA 


Thomas Sueta

Director, Corporate Communications
+1.302.773.3903


[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/chemours-announces-proposed-private-offering-of-750-million-aggregate-principal-amount-of-senior-unsecured-notes-301171892.html

SOURCE The Chemours Company

Contura Signs Agreement to Divest Cumberland Mine, Pennsylvania Assets

Transaction Expected to Accelerate Contura’s Strategic Exit from Thermal Coal Production

PR Newswire

BRISTOL, Tenn., Nov. 12, 2020 /PRNewswire/ — Contura Energy, Inc. (NYSE: CTRA), a leading U.S. supplier of metallurgical products for the steel-making industry, today announced a definitive agreement with Iron Senergy Holding, LLC (Iron Senergy) for the divestment of Contura’s Pennsylvania operations, including the Cumberland Mine in Greene County, Pennsylvania. The equity transaction is expected to close before December 31, 2020, and, upon closing, will transfer to Iron Senergy the subsidiaries that hold Contura’s Cumberland and Emerald mines and the associated coal reserves, mining permits and operations, infrastructure, equipment and transloading facilities.

The purchaser, Iron Senergy, has expressed its intention to continue operating the Cumberland Mine past Contura’s previously announced planned exit at the end of 2022, thereby extending employment opportunities for the Cumberland workforce, providing a continued tax base for the local community, and sustaining business opportunities for Cumberland’s vendors and a reliable fuel supply for customers. Iron Senergy’s plan also includes the development and integration of renewable energy in efforts to further develop synergistic opportunities with regional utilities.

“In addition to the important benefits to Cumberland employees and the local community in Greene County, the signing of this agreement to divest Cumberland provides a way for both Contura and Iron Senergy to advance our respective strategic goals,” said David Stetson, Contura’s chairman and chief executive officer. “This transaction allows Contura to nearly complete our move to a pure-play metallurgical company providing critical feedstock for steel production. Additionally, closing the transaction will meaningfully reduce our asset retirement obligations and collateralization requirements, allowing us to better focus our resources on the core mines in our portfolio and our strategy as solely a met producer.”

According to the terms of the transaction, Iron Senergy will acquire all of the equity of the following wholly-owned Contura subsidiaries upon closing: Emerald Contura, LLC; Cumberland Contura, LLC; Contura Coal Resources, LLC; Contura Pennsylvania Land, LLC; and Contura Pennsylvania Terminal, LLC (together, the Pennsylvania Entities). Upon closing, Iron Senergy will post replacement reclamation bonds for the Pennsylvania Entities and assume their UMWA collective bargaining agreements. Also, upon closing, Contura will provide $20 million in cash consideration to Iron Senergy and will transfer $30 million in existing cash collateral to Iron Senergy’s surety provider as collateral for Iron Senergy’s replacement reclamation bonds.

Iron Senergy will assume all reclamation obligations associated with the Pennsylvania Entities, estimated to be approximately $169 million of undiscounted future cash outflows, which will release Contura from these obligations upon closing of the transaction.

The transaction is subject to a number of conditions to closing, and therefore, there can be no assurances that closing will occur when anticipated, or at all. The parties are working diligently to address all of these conditions.

ABOUT CONTURA ENERGY

Contura Energy (NYSE: CTRA) is a Tennessee-based coal supplier with affiliate mining operations across major coal basins in Pennsylvania, Virginia and West Virginia. With customers across the globe, high-quality reserves and significant port capacity, Contura Energy reliably supplies metallurgical coal to produce steel. For more information, visit

www.conturaenergy.com

.

FORWARD-LOOKING STATEMENTS

This news release includes forward-looking statements. These forward-looking statements are based on Contura’s expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. These factors are difficult to predict accurately and may be beyond Contura’s control. Forward-looking statements in this news release or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Contura to predict these events or how they may affect Contura. Except as required by law, Contura has no duty to, and does not intend to, update or revise the forward-looking statements in this news release or elsewhere after the date this release is issued. In light of these risks and uncertainties, investors should keep in mind that results, events or developments discussed in any forward-looking statement made in this news release may not occur.

INVESTOR CONTACT


[email protected]

Alex Rotonen, CFA
423.956.6882

MEDIA CONTACT


[email protected]

Emily O’Quinn

423.573.0369

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/contura-signs-agreement-to-divest-cumberland-mine-pennsylvania-assets-301171500.html

SOURCE Contura Energy, Inc.

Sypris Reports Third Quarter Results

Sypris Reports Third Quarter Results

Gross Profit Rises 47%; New Contracts Announced

LOUISVILLE, Ky.–(BUSINESS WIRE)–
Sypris Solutions, Inc. (Nasdaq/GM: SYPR) today reported financial results for its third quarter ended October 4, 2020. Having completed a series of strategic initiatives over the past several years, Sypris Solutions is now well positioned to achieve long-term growth and a return to profitable operations. These steps have included reducing and realigning the Company’s cost structure while diversifying its book of business in terms of both customers and markets.

Results for the third quarter of 2020 fundamentally reflected these expectations, highlighted by a rebound in demand for Sypris Technologies from the unusually low levels of the second quarter and the positive performance of Sypris Electronics. The global economic impact of the COVID-19 pandemic lessened in several of the Company’s markets during the quarter, while the essential nature of the defense and communication programs served by Sypris Electronics continued to enable this segment to sustain operations at or above planned levels.

HIGHLIGHTS

─────────────────────

  • The Company’s third quarter revenue was even with the prior-year period, but increased 29.2% sequentially, reflecting a rebound in market conditions for Sypris Technologies and continued growth for Sypris Electronics.
  • Gross profit increased 47.1% quarter-over-quarter and 70.8% sequentially, while gross margin increased 490 basis points from the prior-year period and 370 basis points sequentially.
  • EPS increased to $0.17 per share for the quarter compared to a loss of $0.07 per share for the prior year, reflecting the 47.1% improvement in gross profit and the release of a valuation allowance on certain foreign deferred tax assets, in consideration of the sustained profitability of and positive outlook for the Company’s operations in Mexico, among other factors.
  • Sypris Electronics revenue increased 52.6% during the quarter compared to the prior-year period, supported by a strong backlog of orders, which has increased 27.2% since year-end 2019, while supporting a 62.0% increase in shipments year-to-date over the prior year.
  • During the third quarter, Sypris Electronics announced an initial contract award from the Leonardo DRS Naval Electronics business unit to manufacture and test electronic assemblies for a shipboard system with production to begin during 2020.
  • Sypris Electronics also announced contracts to manufacture a variety of electronic assemblies for mission-critical munition dispensing systems with production to begin during 2020 and continue into 2021.
  • Sypris Technologies revenue increased 62.1% sequentially, as customers reopened operations that were temporarily idled during the second quarter in response to the global pandemic.
  • Gross profit for Sypris Technologies increased 732.8% sequentially, while gross margin increased to 15.8%, up from 3.1% for the second quarter of 2020.
  • Sypris Technologies announced the award of orders for projects in Brazil and Canada. The contracts, which provide for the use of Ultra High-Pressure closures in the Libra Oil Field deep-water project in Brazil and Double-Bolt closures for use in the Trans Mountain Pipeline Expansion project in Canada, call for shipments to begin prior to year-end 2020.
  • Sypris Technologies also announced a contract for the delivery of 58” Tool-less closures weighing 5.5 tons each for use in the Alberta Xpress Gas project, which will expand transmission capacity from Manitoba to delivery locations in the Midwestern and Southern US. Shipments are to be completed prior to year-end.

─────────────────────

“Our operations performed extremely well during the third quarter and returned to profitability as demand rebounded from the adverse conditions incurred during the second quarter,” commented Jeffrey T. Gill, President and Chief Executive Officer. “In the face of the challenges brought on by the pandemic, our businesses pulled together to protect our employees, while balancing the needs of our customers, communities and business partners during these difficult times. The effort and execution by our people resulted in a strong performance for the third quarter.

“Revenue for Sypris Electronics increased 52.6% from the prior-year quarter, reflecting its strong backlog and improved electronic component availability. Sales are up 62.0% for the first nine months of 2020 compared to the prior year, while backlog has increased 27.2% since year-end. We have been designated as an essential supplier to our customers serving the defense and communications industries and as such, our team has done an excellent job making sure that we were able to provide for their increasing needs during the period.

“Demand from customers serving the automotive, commercial vehicle, sport utility, and off-highway markets recovered in the third quarter, resulting in a 62% increase in revenue sequentially. The outlook going forward has also improved significantly for these markets. Recent contract awards in our energy markets are also expected to contribute in the fourth quarter and early 2021 as we remain vigilant in our pursuit of new opportunities to support our growth objectives in the coming year.

“Gross profit for the first nine months of 2020 was $9.0 million, or 14.6% of revenue as compared to gross margin of 11.2% for the full year 2019. Given the current year-to-date margin performance includes the burden of the pandemic’s impact on the second quarter, we are pleased to be maintaining this trend line. Our margins have improved steadily since 2016 and we believe we have the opportunity to continue this into 2021.

“Sypris Technologies has also been designated as an essential supplier to our customers serving the energy and transportation sectors of our country and as a result, our team will continue to take whatever steps are necessary to ensure that the needs of our customers are reliably met without delay.”

Concluding, Mr. Gill said, “Our customer base and the markets we serve are considerably more diversified than at any point in our recent history. As an essential business, we have a responsibility to ensure that our defense, communications, energy, and transportation sectors remain vibrant. We will continue to monitor developments, act promptly to mitigate the risks and take the necessary steps required to ensure deliveries continue to be made in a timely manner.”

Third Quarter Results

The Company reported revenue of $22.2 million for the third quarter ended October 4, 2020, compared to $22.3 million for the prior-year period. Additionally, the Company reported net income of $3.5 million for the third quarter, or $0.17 per diluted share, compared to a net loss of $1.6 million, or $0.07 per share, for the prior-year period. Results for the quarter ended October 4, 2020, include an income tax benefit of $3.2 million, primarily from the release of a valuation allowance on certain foreign deferred tax assets.

The Company updated its quarterly evaluation on the realizability of deferred tax assets associated with its Mexican operating subsidiary as of October 4, 2020. The Mexico operation’s cumulative income before taxes for the trailing 3-year period ended October 4, 2020, is positive, and together with other positive evidence, supports management’s conclusion that a valuation allowance is no longer needed for the foreign deferred tax assets. The release of the valuation allowance and the impact of deferred tax expense for the nine months ended October 4, 2020, resulted in a net tax benefit of $3.2 million for the third quarter.

For the nine months ended October 4, 2020, the Company reported revenue of $61.7 million compared with $66.3 million for the first nine months of 2019. The Company reported net income for the nine-month period of $2.8 million, or $0.14 per diluted share, compared with a net loss of $3.1 million, or $0.15 per share, for the prior-year period. Results for the nine months ended October 4, 2020, include net gains of $0.8 million from the sale of idle assets and an income tax benefit of $3.2 million, primarily from the release of a valuation allowance on certain foreign deferred tax assets. Results for the nine months ended September 29, 2019, include a gain of $1.5 million in connection with a contract settlement with a customer and net gains of $0.5 million from the sale of idle assets.

Sypris Technologies

Revenue for Sypris Technologies was $12.1 million in the third quarter of 2020 compared to $15.7 million for the prior-year period, primarily reflecting reduced demand attributable to the pandemic coupled with the anticipated cyclical decline in the commercial vehicle market. Gross profit for the third quarter was $1.9 million, or 15.8% of revenue, compared to $2.5 million, or 16.1% of revenue, for the same period in 2019.

Sypris Electronics

Revenue for Sypris Electronics was $10.1 million in the third quarter of 2020 compared to $6.6 million for the prior-year period. Shipments during the third quarter reflected the impact of the growing backlog. Additionally, many of the challenges faced during the prior year with electronic component shortages and extensive lead-times have been resolved. Gross profit for the quarter was $1.5 million, or 15.0% of revenue, compared to a loss of $0.2 million, or 2.8% of revenue, for the same period in 2019.

Outlook

Commenting on the future, Mr. Gill added, “First and foremost, we remain focused on the health and safety of our employees, their families and our customers. While the future potential impact of a second wave of the pandemic remains unknown, demand has strengthened significantly from customers serving the automotive, commercial vehicle and sport utility markets. Similarly, demand from customers in the defense and communications sector remains robust. While the energy market continues to be volatile, we continue to see wins on important large projects around the world.

“As we close out this year and prepare for 2021, we remain focused on meeting the important needs of our customers who serve defense, communications, energy, transportation, and other critical infrastructure industries. With a strong backlog and recovering markets, we believe that the outlook for the coming year has the potential to be one of positive top line growth and further margin expansion for Sypris. We are increasingly optimistic about the coming year.”

Sypris Solutions is a diversified provider of truck components, oil and gas pipeline components and aerospace and defense electronics. The Company produces a wide range of manufactured products, often under multi-year, sole-source contracts. For more information about Sypris Solutions, visit its Web site at www.sypris.com.

Forward Looking Statements

This press release contains “forward-looking” statements within the meaning of the federal securities laws.Forward-looking statements include our plans and expectations of future financial and operational performance. Such statements may relate to projections of the company’s revenue, earnings, and other financial and operational measures, our liquidity, our ability to mitigate or manage disruptions posed by COVID-19, and the impact of COVID-19 and economic conditions on our future operations, among other matters. In March 2020, the President of the United States declared the COVID-19 outbreak a national emergency. COVID-19 continues to spread throughout the United States and other countries across the world, and the duration and severity of its effects are currently unknown. The COVID-19 pandemic has resulted, and is likely to continue to result, in significant economic disruption and has and will likely adversely affect our business. The Company has continued to operate at each location and sought to remain compliant with government regulations imposed due to the COVID-19 pandemic.

Each forward-looking statement herein is subject to risks and uncertainties, as detailed in our most recent Form 10-K and Form 10-Q and other SEC filings. Briefly, we currently believe that such risks also include the following: the impact of COVID-19 and economic conditions on our future operations; possible public policy response to the pandemic, including legislation or restrictions that may impact our operations or supply chain; our failure to successfully complete final contract negotiations with regard to our announced contract “orders”, “wins” or “awards”; our failure to achieve and maintain profitability on a timely basis by steadily increasing our revenues from profitable contracts with a diversified group of customers, which would cause us to continue to use existing cash resources or other assets to fund operating losses; our failure to achieve targeted gains and cash proceeds from the anticipated sale of certain equipment; the fees, costs and supply of, or access to, debt, equity capital, or other sources of liquidity; our ability to comply with the requirements of the SBA and seek forgiveness of all or a portion of the PPP Loan; the cost, quality, timeliness, efficiency and yield of our operations and capital investments, including the impact of tariffs, product recalls or related liabilities, employee training, working capital, production schedules, cycle times, scrap rates, injuries, wages, overtime costs, freight or expediting costs; dependence on, retention or recruitment of key employees and distribution of our human capital; disputes or litigation involving governmental, supplier, customer, employee, creditor, stockholder, product liability or environmental claims; our inability to develop new or improved products or new markets for our products; cost, quality and availability or lead times of raw materials such as steel, component parts (especially electronic components), natural gas or utilities; breakdowns, relocations or major repairs of machinery and equipment, especially in our Toluca Plant; our ability to maintain compliance with the NASDAQ listing standards minimum closing bid price; our reliance on a few key customers, third party vendors and sub-suppliers; inventory valuation risks including excessive or obsolescent valuations or price erosions of raw materials or component parts on hand or other potential impairments, non-recoverability or write-offs of assets or deferred costs; other potential weaknesses in internal controls over financial reporting and enterprise risk management; failure to adequately insure or to identify product liability, environmental or other insurable risks; unanticipated or uninsured disasters, public health crises, losses or business risks; unanticipated or uninsured product liability claims; volatility of our customers’ forecasts, scheduling demands and production levels which negatively impact our operational capacity and our effectiveness to integrate new customers or suppliers, and in turn cause increases in our inventory and working capital levels; the costs of compliance with our auditing, regulatory or contractual obligations; labor relations; strikes; union negotiations; pension valuation, health care or other benefit costs; our inability to patent or otherwise protect our inventions or other intellectual property from potential competitors; adverse impacts of new technologies or other competitive pressures which increase our costs or erode our margins; U.S. government spending on products and services that Sypris Electronics provides, including the timing of budgetary decisions; changes in licenses, security clearances, or other legal rights to operate, manage our work force or import and export as needed; risks of foreign operations; currency exchange rates; war, terrorism, or political uncertainty; cyber security threats and disruptions; inaccurate data about markets, customers or business conditions; or unknown risks and uncertainties. We undertake no obligation to update our forward-looking statements, except as may be required by law.

 
Sypris Solutions, Inc.
Financial Highlights
(In thousands, except per share amounts)
 
Three Months Ended
October 4, September 29,

2020

2019

(Unaudited)
Revenue

$

22,154

$

22,259

 

Net income (loss)

$

3,495

$

(1,557

)

Income (loss) per common share:
Basic

$

0.17

$

(0.07

)

Diluted

$

0.17

$

(0.07

)

Weighted average shares outstanding:
Basic

 

21,064

 

20,941

 

Diluted

 

21,080

 

20,941

 

 
 
 
 
Nine Months Ended
October 4, September 29,

2020

2019

(Unaudited)
Revenue

$

61,732

$

66,267

 

Net income (loss)

$

2,842

$

(3,090

)

Income (loss) per common share:
Basic

$

0.14

$

(0.15

)

Diluted

 

0.14

 

(0.15

)

Weighted average shares outstanding:
Basic

 

21,026

 

20,829

 

Diluted

 

21,026

 

20,829

 

 
Sypris Solutions, Inc.
Consolidated Statements of Operations
(in thousands, except for per share data)
 
Three Months Ended Nine Months Ended
October 4, September 29, October 4, September 29,

2020

2019

2020

2019

(Unaudited) (Unaudited)
Net revenue:
Sypris Technologies

$

12,072

 

$

15,654

 

$

33,234

 

$

48,673

 

Sypris Electronics

 

10,082

 

 

6,605

 

 

28,498

 

 

17,594

 

Total net revenue

 

22,154

 

 

22,259

 

 

61,732

 

 

66,267

 

Cost of sales:
Sypris Technologies

 

10,165

 

 

13,140

 

 

28,605

 

 

40,892

 

Sypris Electronics

 

8,568

 

 

6,793

 

 

24,112

 

 

18,200

 

Total cost of sales

 

18,733

 

 

19,933

 

 

52,717

 

 

59,092

 

Gross profit (loss):
Sypris Technologies

 

1,907

 

 

2,514

 

 

4,629

 

 

7,781

 

Sypris Electronics

 

1,514

 

 

(188

)

 

4,386

 

 

(606

)

Total gross profit

 

3,421

 

 

2,326

 

 

9,015

 

 

7,175

 

Selling, general and administrative

 

2,577

 

 

3,148

 

 

8,630

 

 

10,206

 

Severance, relocation and other costs

 

 

 

190

 

 

124

 

 

391

 

Operating income (loss)

 

844

 

 

(1,012

)

 

261

 

 

(3,422

)

Interest expense, net

 

216

 

 

227

 

 

636

 

 

676

 

Other expense (income), net

 

372

 

 

286

 

 

(114

)

 

(1,156

)

Income (loss) before taxes

 

256

 

 

(1,525

)

 

(261

)

 

(2,942

)

Income tax (benefit) expense, net

 

(3,239

)

 

32

 

 

(3,103

)

 

148

 

Net Income (loss)

$

3,495

 

$

(1,557

)

$

2,842

 

$

(3,090

)

Income (loss) per common share:
Basic

$

0.17

 

$

(0.07

)

$

0.14

 

$

(0.15

)

Diluted

$

0.17

 

$

(0.07

)

$

0.14

 

$

(0.15

)

Dividends declared per common share

$

 

$

 

$

 

$

 

Weighted average shares outstanding:
Basic

 

21,064

 

 

20,941

 

 

21,026

 

 

20,829

 

Diluted

 

21,080

 

 

20,941

 

 

21,026

 

 

20,829

 

 
Sypris Solutions, Inc.
Consolidated Balance Sheets
(in thousands, except for share data)
 
October 4, December 31,

2020

2019

(Unaudited) (Note)
ASSETS
Current assets:
Cash and cash equivalents

$

8,294

 

$

5,095

 

Accounts receivable, net

 

8,603

 

 

7,444

 

Inventory, net

 

17,844

 

 

20,784

 

Other current assets

 

4,766

 

 

4,282

 

Assets held for sale

 

1,069

 

 

2,233

 

Total current assets

 

40,576

 

 

39,838

 

Property, plant and equipment, net

 

9,727

 

 

11,675

 

Operating lease right-of-use assets

 

6,315

 

 

7,014

 

Other assets

 

4,760

 

 

1,529

 

Total assets

$

61,378

 

$

60,056

 

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable

$

8,202

 

$

9,346

 

Accrued liabilities

 

12,583

 

 

12,495

 

Operating lease liabilities, current portion

 

942

 

 

841

 

Finance lease obligations, current portion

 

383

 

 

684

 

Note payable – related party, current portion

 

2,500

 

 

 

Note payable – PPP loan, current portion

 

2,174

 

 

 

Total current liabilities

 

26,784

 

 

23,366

 

 
Operating lease liabilities, net of current portion

 

6,189

 

 

6,906

 

Finance lease obligations, net of current portion

 

2,029

 

 

2,351

 

Note payable – related party

 

3,974

 

 

6,463

 

Note payable – PPP Loan

 

1,384

 

 

 

Other liabilities

 

5,816

 

 

7,539

 

Total liabilities

 

46,176

 

 

46,625

 

Stockholders’ equity:
Preferred stock, par value $0.01 per share, 975,150 shares authorized; no shares issued

 

 

 

 

Series A preferred stock, par value $0.01 per share, 24,850 shares authorized; no shares issued

 

 

 

 

Common stock, non-voting, par value $0.01 per share, 10,000,000 shares authorized; no shares issued

 

 

 

 

Common stock, par value $0.01 per share, 30,000,000 shares authorized;
21,321,790 shares issued and 21,316,752 outstanding in 2020 and
21,324,618 shares issued and 21,298,426 outstanding in 2019

 

213

 

 

213

 

Additional paid-in capital

 

155,004

 

 

154,702

 

Accumulated deficit

 

(114,591

)

 

(117,433

)

Accumulated other comprehensive loss

 

(25,424

)

 

(24,051

)

Treasury stock, 5,038 and 26,192 in 2020 and 2019

 

 

 

 

Total stockholders’ equity

 

15,202

 

 

13,431

 

Total liabilities and stockholders’ equity

$

61,378

 

$

60,056

 

 
Note: The balance sheet at December 31, 2019, has been derived from the audited consolidated financial statements at that date but does not include all information and footnotes required by accounting principles generally accepted in the United States for a complete set of financial statements.
 
 
Sypris Solutions, Inc.
Consolidated Cash Flow Statements
(in thousands)
 
Nine Months Ended
October 4, September 29,

2020

2019

(Unaudited)
Cash flows from operating activities:
Net income (loss)

$

2,842

 

$

(3,090

)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization

 

1,883

 

 

2,106

 

Deferred income taxes

 

(3,257

)

 

 

Stock-based compensation expense

 

335

 

 

389

 

Deferred loan costs recognized

 

11

 

 

11

 

Net (gain) loss on the sale of assets

 

(813

)

 

(467

)

Provision for excess and obsolete inventory

 

222

 

 

503

 

Non-cash lease expense

 

699

 

 

541

 

Other noncash items

 

72

 

 

15

 

Contributions to pension plans

 

(34

)

 

(348

)

Changes in operating assets and liabilities:
Accounts receivable

 

(1,158

)

 

1,198

 

Inventory

 

2,409

 

 

(2,415

)

Prepaid expenses and other assets

 

(983

)

 

207

 

Accounts payable

 

(1,036

)

 

(3,344

)

Accrued and other liabilities

 

(1,114

)

 

1,646

 

Net cash provided by (used in) operating activities

 

78

 

 

(3,048

)

Cash flows from investing activities:
Capital expenditures

 

(1,151

)

 

(553

)

Proceeds from sale of assets

 

1,969

 

 

653

 

Net cash provided by investing activities

 

818

 

 

100

 

Cash flows from financing activities:
Finance lease payments

 

(623

)

 

(466

)

Proceeds from Paycheck Protection Program loan

 

3,558

 

 

 

Indirect repurchase of shares for minimum statutory tax withholdings

 

(33

)

 

(138

)

Net cash provided by (used in) financing activities

 

2,902

 

 

(604

)

Effect of exchange rate changes on cash balances

 

(599

)

 

(99

)

Net increase (decrease) in cash and cash equivalents

 

3,199

 

 

(3,651

)

Cash and cash equivalents at beginning of period

 

5,095

 

 

10,704

 

Cash and cash equivalents at end of period

$

8,294

 

$

7,053

 

 

 

Anthony C. Allen

Chief Financial Officer

(502) 329-2000

KEYWORDS: Kentucky United States North America

INDUSTRY KEYWORDS: Other Energy Automotive Manufacturing Aerospace Oil/Gas Manufacturing Energy Other Manufacturing

MEDIA:

Logo
Logo

Tufin to Add IPAM Security Policy App to its Marketplace

Tufin to Add IPAM Security Policy App to its Marketplace

The company will also release updates to its Vulnerability Mitigation App

BOSTON–(BUSINESS WIRE)–Tufin® (NYSE: TUFN), a company pioneering a policy-centric approach to security and IT operations, today announced the release of the Tufin IPAM Security Policy (ISP) App, the latest addition to the Tufin Marketplace. Providing out-of-the-box integration with leading IPAM solutions, the new app ensures that network changes made through IPAM are visible to network security teams and are consistent with established network security policies.

Network security teams face many challenges when it comes to maintaining accurate segmentation strategies. With frequent changes to the network and a lack of communication between network and security teams, maintaining consistency is difficult. Even in cases where changes are communicated across these teams, it is still virtually impossible to assess in real-time how these changes impact network security posture.

Tufin’s IPAM Security Policy App allows users to gain accurate and up-to-date network visibility of all used network (IP) addresses from a single source of truth. Network visibility is maintained even as IP address assignments are changed in IPAM, breaking down the traditional silos between network and security teams. With the IPAM Security Policy App, users can achieve consistent security policy management across their dynamic and ever-changing hybrid networks.

“Tufin’s IPAM Security Policy App is an important addition to the Tufin Marketplace,” said Ofer Or, Vice President of Products at Tufin. “The app is yet further proof that we’re on a mission to offer our customers the most comprehensive security policy management capabilities across the security ecosystem, leverage data gathered in multiple systems and improve their security posture.”

“The integration with Tufin’s IPAM Security Policy App complements our event-based notification integration, bringing a standard automated approach suitable for network installations of all sizes. It leverages our accurate data repository (Network Source of Truth) to improve teamwork and better connect networking and security silos” said Ronan David, VP Strategy at EfficientIP. “We’re excited to deliver these benefits to our customers.”

The IPAM Security Policy App is available for existing customers through the early access program, and will be generally available on the Tufin Marketplace on December 1, 2020.

Enhanced capabilities of the Tufin Vulnerability Mitigation App

Tufin will also release an update to its Vulnerability Mitigation App (VMA) that allows organizations to prioritize remediation and mitigation efforts by enhancing vulnerability data with network insights. The latest version of VMA adds the following new capabilities:

  • Support for disabling access and restoring access to vulnerable/patched assets using the Group Object Modification workflow. This workflow provides the ability to enforce temporary mitigation of access, to allow time for remediation and to restore connectivity once patched.
  • Topology-based analysis to determine if network and host-based vulnerabilities are exposed to the Internet, or other untrusted zones, through the exploitable service.
  • Reporting based on most prevalent exposed vulnerable assets and most exposed zones.

The Vulnerability Mitigation App is now available on the Tufin Marketplace, and the latest version of the app will be generally available on December 1, 2020.

About Tufin

Tufin (NYSE: TUFN) simplifies management of some of the largest, most complex networks in the world, consisting of thousands of firewall and network devices and emerging hybrid cloud infrastructures. Enterprises select the Tufin Orchestration Suite™ to increase agility in the face of ever-changing business demands while maintaining a robust security posture. The Suite reduces the attack surface and meets the need for greater visibility into secure and reliable application connectivity. With over 2,000 customers since its inception, Tufin’s network security automation enables enterprises to implement changes in minutes instead of days, while improving their security posture and business agility.

Find out more at: www.tufin.com

Follow Tufin on Twitter: @TufinTech

Read more on Tufin’s blog: Suite Talk

Susan Rivera

Corporate Communications Manager, Tufin

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Software Technology Security

MEDIA:

Logo
Logo

Tufin Announces Third Quarter 2020 Results

Tufin Announces Third Quarter 2020 Results

Third quarter revenue of $25.6 million remained relatively flat year-over-year

GAAP operating loss of $5.0 million and non-GAAP operating loss of $1.0 million represent year-over-year improvement

BOSTON & TEL AVIV, Israel–(BUSINESS WIRE)–Tufin (NYSE: TUFN), a company pioneering a policy-centric approach to security and IT operations, today announced financial results for the third quarter ended September 30, 2020.

“Our business improved meaningfully in the third quarter, relative to first half year results that were significantly impacted by the COVID-19 pandemic,” said Ruvi Kitov, CEO and co-founder of Tufin. “We are seeing positive signs in the marketplace as demand for our core products is growing, driven by the accelerating trends of automation and Zero-Trust. At the same time, SecureCloud, which we launched in the first quarter this year, is gaining traction as large enterprises move into the cloud. Due to actions taken earlier in the year, our costs are lower, and our balance sheet is strong. While uncertainty remains higher than normal, we believe that Tufin is well positioned to achieve our long-term growth objectives, addressing a large and expanding market.”

Financial Highlights for the Third Quarter Ended September 30, 2020

Revenue:

  • Total revenue was $25.6 million, relatively flat compared with the third quarter of 2019.
  • Product revenue was $10.0 million, down 13.1% compared with the third quarter of 2019.
  • Maintenance and professional services revenue was $15.6 million, up 10.8% compared with the third quarter of 2019.

Gross Profit:

  • GAAP gross profit was $21.0 million, or 82% of total revenue, compared to $20.7 million in the third quarter of 2019, or 81% of total revenue.
  • Non-GAAP gross profit was $21.6 million, or 84% of total revenue, compared to $21.0 million in the third quarter of 2019, or 82% of total revenue.

Operating Loss:

  • GAAP operating loss was $5.0 million, compared to $7.7 million in the third quarter of 2019.
  • Non-GAAP operating loss was $1.0 million, compared to $5.1 million in the third quarter of 2019.

Net Loss:

  • GAAP net loss was $5.1 million, or a loss of $0.14 per share, compared to a GAAP net loss of $8.3 million, or a loss of $0.24 per share, in the third quarter of 2019.
  • Non-GAAP net loss was $1.2 million, or a loss of $0.03 per share, compared to a loss of $5.7 million, or a loss of $0.17 per share, in the third quarter of 2019.

Balance Sheet and Cash Flow:

  • Cash flow used for operating activities during the nine months ended September 30, 2020 was $15.7 million, compared to cash flow used for operating activities of $3.0 million during the nine months ended September 30, 2019.
  • Total cash, cash equivalents, restricted cash and marketable securities as of September 30, 2020 were $103.6 million, compared to $121.7 million as of December 31, 2019.

The tables at the end of this press release include a reconciliation of GAAP to non-GAAP gross profit, operating income and net income for the three and nine months ended September 30, 2020 and 2019. An explanation of these measures is also included under the heading “Non-GAAP Financial Measures.”

Recent Business Highlights

  • Announced the release of the Tufin IPAM Security Policy (ISP) App, the latest addition to the Tufin Marketplace. The ISP App provides out-of-the-box integration with leading IPAM solutions and ensures that network changes made through IPAM are visible to network security teams and are consistent with established network security policies.
  • Held Tufinnovate annual user event in September 2020, attracting a record number of customers and prospects.

2020 Outlook

Based on information available as of November 12, 2020, Tufin is issuing guidance as indicated below:

For the fourth quarter 2020:

  • Total revenue between $24 million and $29 million.
  • Non-GAAP operating loss between $5.9 million and $1.6 million.

For the full year 2020:

  • Total revenue between $93.9 million and $98.9 million.
  • Non-GAAP operating loss between $24.7 million and $20.4 million.

Guidance does not contemplate a further deterioration in global economic conditions related to the COVID-19 pandemic. Should macro-economic conditions deteriorate significantly during the remainder of the quarter, either due to government-imposed lockdowns or otherwise, our results could be impacted.

Conference Call Information

To participate in Tufin’s third quarter earnings conference call, please dial (866) 211-3126 (United States) or (647) 689-6579 (international) and enter Conference ID# 5285381. The call will also be webcast live on Tufin’s Investor Relations website at investors.tufin.com. Following the conference call, a replay will be available at (800) 585-8367 (United States) or (416) 621-4642 (international). The replay passcode is 5285381. An archived webcast of this conference call will be available on the investor relations section of the company website.

About Tufin

Tufin (NYSE: TUFN) simplifies management of some of the largest, most complex networks in the world, consisting of thousands of firewall and network devices and emerging hybrid cloud infrastructures. Enterprises select the company’s Tufin Orchestration Suite™ to increase agility in the face of ever-changing business demands while maintaining a robust security posture. The Suite reduces the attack surface and meets the need for greater visibility into secure and reliable application connectivity. With over 2,000 customers since its inception, Tufin’s network security automation enables enterprises to implement changes in minutes instead of days, while improving their security posture and business agility.

Non-GAAP Financial Measures

We believe that providing non-GAAP financial measures that exclude, as applicable, share-based compensation expense and certain non-recurring costs, as well as, the tax effect of these non-GAAP adjustments, allows for more meaningful comparisons between our operating results from period to period. These non-GAAP financial measures are an important tool for financial and operational decision-making and for evaluating our operating results over different periods:

  • We define non-GAAP gross profit as gross profit excluding share-based compensation expense.
  • We define non-GAAP operating profit (loss) as operating profit (loss) excluding share-based compensation expense, shelf registration costs and one-time expenses associated with the reorganization of one of our subsidiaries.
  • We define non-GAAP net income (loss) as net income (loss) excluding share-based compensation expense, shelf registration costs, one-time expenses associated with the reorganization of one of our subsidiaries and the tax effect of these non-GAAP adjustments.

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expense, we believe that providing non-GAAP financial measures that exclude non-cash share-based compensation expense allow for more meaningful comparisons between our operating results from period to period. In addition, we believe that providing non-GAAP financial measures that exclude shelf registration costs and one-time expenses associated with the reorganization of one of our subsidiaries allows for more meaningful comparisons between our operating results from period to period since these non-recurring costs are not representative or indicative of our ongoing operations. We also believe that the tax effects related to the non-GAAP adjustments set forth above do not reflect the performance of our core business and would impact period-to-period comparability.

Other companies, including companies in our industry, may calculate non-GAAP gross profit, non-GAAP operating profit (loss) and non-GAAP net income (loss) differently or not at all, which reduces the usefulness these non-GAAP financial measures for comparison. You should consider these non-GAAP financial measures along with other financial performance measures, including gross profit, operating profit (loss) and net income (loss), and our financial results presented in accordance with U.S. GAAP. Tufin urges investors to review the reconciliation of its non-GAAP financial measures to the comparable U.S. GAAP financial measures included below, and not to rely on any single financial measure to evaluate its business.

Guidance for non-GAAP financial measures excludes, as applicable, share-based compensation expense and certain non-recurring costs. A reconciliation of the non-GAAP financial measures guidance to the corresponding GAAP measures is not available on a forward-looking basis due to the uncertainty regarding, and the potential variability and significance of, the amounts of share-based compensation expense and certain non-recurring costs, as applicable, that are excluded from the guidance. Accordingly, a reconciliation of the non-GAAP financial measures guidance to the corresponding GAAP measures for future periods is not available without unreasonable effort.

Cautionary Language Concerning Forward-Looking Statements

This release contains forward-looking statements, which express the current beliefs and expectations of Tufin’s (the “Company”) management. In some cases, forward-looking statements may be identified by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential” or the negative of these terms or other similar expressions. Such statements involve a number of known and unknown risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: the impact of COVID-19 on the budgets of our clients and on economic conditions generally; changes in the rapidly evolving enterprise network landscape; failure to effectively manage growth; potential near-term declines in our operating and net profit margins and our revenue growth rate; real or perceived shortcomings, defects or vulnerabilities in the Company’s solutions or internal network system, or the failure of the Company’s customers or channel partners to correctly implement the Company’s solutions; fluctuations in quarterly results of operations; the inability to acquire new customers or sell additional products and services to existing customers; competition from a wide variety of competitive vendors; the Company’s ability to successfully integrate potential future acquisitions; and other factors discussed under the heading “Risk Factors” in the Company’s annual report on Form 20-F filed with the Securities and Exchange Commission on March 18, 2020. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

 

TUFIN SOFTWARE TECHNOLOGIES LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

(Unaudited)

 

 

 

December 31,

 

 

September 30,

 

 

 

2019

 

 

2020

 

Assets

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

Cash and cash equivalents

 

 

118,661

 

 

 

74,380

 

Restricted bank deposits

 

 

224

 

 

 

234

 

Marketable Securities – short term

 

 

 

 

 

10,045

 

Accounts receivable (net of allowance for doubtful accounts of $77 and $51 at December 31, 2019 and September 30, 2020, respectively)

 

 

16,222

 

 

 

11,642

 

Prepaid expenses and other current assets

 

 

4,773

 

 

 

7,550

 

Total current assets

 

 

139,880

 

 

 

103,851

 

NON CURRENT ASSETS:

 

 

 

 

 

 

 

 

Long-term restricted bank deposits

 

 

2,844

 

 

 

2,853

 

Marketable Securities – long term

 

 

 

 

 

16,133

 

Property and equipment, net

 

 

4,177

 

 

 

4,803

 

Deferred costs

 

 

5,640

 

 

 

5,516

 

Deferred tax assets

 

 

1,659

 

 

 

1,502

 

Operating lease assets

 

 

20,958

 

 

 

19,363

 

Other non-current assets

 

 

1,574

 

 

 

1,476

 

Total non-current assets

 

 

36,852

 

 

 

51,646

 

Total assets

 

 

176,732

 

 

 

155,497

 

 

TUFIN SOFTWARE TECHNOLOGIES LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except share data)

(Unaudited)

 

 

 

December 31,

 

 

September 30,

 

 

 

2019

 

 

2020

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

Trade payables

 

 

4,394

 

 

 

4,513

 

Employee and payroll accrued expenses

 

 

15,422

 

 

 

14,373

 

Other accounts payables

 

 

1,568

 

 

 

661

 

Operating lease liabilities – current

 

 

2,533

 

 

 

2,996

 

Deferred revenues

 

 

22,725

 

 

 

24,733

 

Total current liabilities

 

 

46,642

 

 

 

47,276

 

NON-CURRENT LIABILITIES:

 

 

 

 

 

 

 

 

Long-term deferred revenues

 

 

12,838

 

 

 

12,088

 

Non-current operating lease liabilities

 

 

22,000

 

 

 

19,722

 

Other non-current liabilities

 

 

930

 

 

 

1,038

 

Total non-current liabilities

 

 

35,768

 

 

 

32,848

 

Total liabilities

 

 

82,410

 

 

 

80,124

 

 

 

 

 

 

 

 

 

 

SHAREHOLDERS’ EQUITY:

 

 

 

 

 

 

 

 

Ordinary shares of NIS 0.015 par value; 150,000,000 shares authorized at December 31, 2019 and September 30, 2020, respectively; 35,230,253 and 35,796,817 shares issued and outstanding at December 31, 2019 and September 30, 2020, respectively;

 

 

145

 

 

 

147

 

Additional paid-in capital

 

 

162,609

 

 

 

174,652

 

Accumulated other comprehensive income

 

 

 

 

 

10

 

Accumulated deficit

 

 

(68,432)

 

 

 

(99,436)

 

TOTAL SHAREHOLDERS’ EQUITY

 

 

94,322

 

 

 

75,373

 

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

176,732

 

 

 

155,497

 

         

TUFIN SOFTWARE TECHNOLOGIES LTD.

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

U.S. dollars in thousands (except per share data)

 

(Unaudited)

 
         

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

September 30,

 

September 30,

 

 

2019

 

 

2020

 

 

2019

 

2020

 

Revenues:

 

 

 

 

 

 

 

 

 

Product

11,510

 

 

10,000

 

 

33,030

 

23,705

 

Maintenance and professional services

14,090

 

 

15,606

 

 

40,125

 

46,177

 

Total revenues

25,600

 

 

25,606

 

 

73,155

 

69,882

 

Cost of revenues:

 

 

 

 

 

 

 

 

 

 

Product

608

 

 

523

 

 

2,138

 

1,736

 

Maintenance and professional services

4,317

 

 

4,044

 

 

11,728

 

13,157

 

Total cost of revenues

4,925

 

 

4,567

 

 

13,866

 

14,893

 

Gross profit

20,675

 

 

21,039

 

 

59,289

 

54,989

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Research and development

8,331

 

 

8,071

 

 

22,298

 

26,282

 

Sales and marketing

16,161

 

 

12,988

 

 

46,913

 

44,453

 

General and administrative

3,844

 

 

4,994

 

 

9,721

 

14,718

 

Total operating expenses

28,336

 

 

26,053

 

 

78,932

 

85,453

 

Operating loss

(7,661)

 

 

(5,014)

 

 

(19,643)

 

(30,464)

 

Financial income (expense), net

(342)

 

 

240

 

 

(579)

 

676

 

Loss before taxes on income

(8,003)

 

 

(4,774)

 

 

(20,222)

 

(29,788)

 

Taxes on income

(279)

 

 

(373)

 

 

(722)

 

(1,216)

 

Net loss

(8,282)

 

 

(5,147)

 

 

(20,944)

 

(31,004)

 

Basic and diluted net loss per ordinary share

(0.24)

 

 

(0.14)

 

 

(0.85)

 

(0.87)

 

Weighted average number of shares used in computing net loss per ordinary share, basic and diluted

34,145

 

 

35,758

 

 

24,721

 

35,621

 

 

Share-based Compensation Expense:

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

 

September 30,

 

September 30,

 

 

2019

 

2020

 

2019

 

2020

Cost of revenues

 

341

 

574

 

887

 

1,536

Research and development

 

505

 

1,244

 

1,120

 

3,427

Sales and marketing

 

1,083

 

1,118

 

3,083

 

3,327

General and administrative

 

671

 

1,056

 

1,245

 

2,894

Total share-based compensation expense

 

2,600

 

3,992

 

6,335

 

11,184

 

TUFIN SOFTWARE TECHNOLOGIES LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

(Unaudited)

 

 

 

Nine Months Ended

 

 

 

September 30,

 

 

 

2019

 

 

2020

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

 

(20,944)

 

 

 

(31,004)

 

Adjustment to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation

 

 

881

 

 

 

1,068

 

Bad debt expense

 

 

31

 

 

 

51

 

Share-based compensation

 

 

6,335

 

 

 

11,184

 

Amortization of premium on marketable securities

 

 

 

 

 

35

 

Exchange rate differences on cash, cash equivalents and restricted cash

 

 

(314)

 

 

 

276

 

 

 

 

 

 

 

 

 

 

Change in operating assets and liabilities items:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

2,856

 

 

 

4,529

 

Prepaid expenses and other current assets

 

 

(23)

 

 

 

(3,126)

 

Deferred costs

 

 

(7)

 

 

 

232

 

Deferred taxes and other non-current assets

 

 

(2,059)

 

 

 

255

 

Trade payables

 

 

1,134

 

 

 

119

 

Employee and payroll accrued expenses

 

 

2,247

 

 

 

184

 

Other accounts payable and non-current liabilities

 

 

(1,872)

 

 

 

(533)

 

Operating lease

 

 

2,587

 

 

 

(220)

 

Deferred revenues

 

 

6,140

 

 

 

1,258

 

Net cash used in operating activities

 

 

(3,008)

 

 

 

(15,692)

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Purchase of fixed assets

 

 

(2,168)

 

 

 

(1,960)

 

Investment in marketable securities

 

 

 

 

 

(26,182)

 

Other investing activities

 

 

(172)

 

 

 

 

Net cash used in investing activities

 

 

(2,340)

 

 

 

(28,142)

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Proceeds from initial public offering, net of underwriters’ discounts

 

 

115,292

 

 

 

 

Payments of offering costs related to initial public offering

 

 

(2,645)

 

 

 

 

Proceeds from exercise of share options

 

 

840

 

 

 

1,081

 

Changes in withholding tax related to employee stock plans

 

 

 

 

 

(1,233)

 

Payment of long-term loan

 

 

(222)

 

 

 

 

Net cash provided by (used in) financing activities

 

 

113,265

 

 

 

(152)

 

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

 

337

 

 

 

(276)

 

 

 

 

 

 

 

 

 

 

INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

 

 

108,254

 

 

 

(44,262)

 

 

 

 

 

 

 

 

 

 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD

 

 

17,598

 

 

 

121,729

 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD

 

 

125,852

 

 

 

77,467

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

 

 

 

 

 

 

 

 

Property and equipment purchased but not yet paid

 

 

202

 

 

 

 

Unpaid offering costs

 

 

58

 

 

 

 

 

TUFIN SOFTWARE TECHNOLOGIES LTD.

RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES

U.S. dollars in thousands (except per share data)

(Unaudited)

 

Reconciliation of Gross Profit to Non-GAAP Gross Profit:

 

 

 

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September

30,

 

 

September

30,

 

 

September

30,

 

 

September

30,

 

 

2019

 

 

2020

 

 

2019

 

 

2020

 

Gross profit

20,675

 

 

21,039

 

 

59,289

 

 

54,989

 

Plus:

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation

341

 

 

574

 

 

887

 

 

1,536

 

Non-GAAP gross profit

21,016

 

 

21,613

 

 

60,176

 

 

56,525

 

 

 

Reconciliation of Operating Loss to Non-GAAP Operating Loss:

 

 

 

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September

30,

 

 

September

30,

 

 

September

30,

 

 

September

30,

 

 

2019

 

 

2020

 

 

2019

 

 

2020

 

Operating loss

(7,661)

 

 

(5,014)

 

 

(19,643)

 

 

(30,464)

 

Plus:

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation

 

2,600

 

 

3,992

 

 

6,335

 

 

 

11,184

 

Shelf registration costs

 

 

 

 

 

 

 

 

 

 

 

126

 

One-time reorganization charges

 

 

 

 

 

 

 

 

 

322

 

Non-GAAP operating loss

(5,061)

 

 

(1,022)

 

 

(13,308)

 

 

(18,832)

 

 

 

Reconciliation of Net Loss to Non-GAAP Net Loss:

 

 

 

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September

30,

 

 

September

30,

 

 

September

30,

 

 

September

30,

 

 

2019

 

 

2020

 

 

2019

 

 

2020

 

Net loss

(8,282)

 

 

(5,147)

 

 

(20,944)

 

 

(31,004)

 

Plus:

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation

 

2,600

 

 

3,992

 

 

6,335

 

 

 

11,184

 

Shelf registration costs

 

 

 

 

 

 

 

 

126

 

One-time reorganization charges

 

 

 

 

 

 

 

 

322

 

Taxes on income related to non-GAAP adjustments

 

 

(18)

 

 

 

 

(285)

 

Non-GAAP net loss

(5,682)

 

 

(1,173)

 

 

(14,609)

 

 

(19,657)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP net income per share – basic and diluted

 

(0.17)

 

 

(0.03)

 

 

(0.59)

 

 

 

(0.55)

 

Weighted average number of shares

34,145

 

 

35,758

 

 

24,721

 

 

35,621

 

About Tufin

Tufin (NYSE: TUFN) simplifies management of some of the largest, most complex networks in the world, consisting of thousands of firewall and network devices and emerging hybrid cloud infrastructures. Enterprises select the Tufin Orchestration Suite™ to increase agility in the face of ever-changing business demands while maintaining a robust security posture. The Suite reduces the attack surface and meets the need for greater visibility into secure and reliable application connectivity. With over 2,000 customers since its inception, Tufin’s network security automation enables enterprises to implement changes in minutes instead of days, while improving their security posture and business agility.

Find out more at: www.tufin.com

Follow Tufin on Twitter: @TufinTech

Read more on Tufin’s blog: Suite Talk

Investor Relations Contact:

Ryan Burkart

[email protected]

Media Contact:

Susan Rivera

Corporate Communications, Tufin

[email protected]

KEYWORDS: Massachusetts United States North America Israel Middle East

INDUSTRY KEYWORDS: Data Management Security Technology Other Technology Software Networks

MEDIA:

Logo
Logo

The Chemours Company Announces Conditional Redemption And Cash Tender Offer And Consent Solicitation For Any And All Of Its 6.625% Senior Notes Maturing In 2023

PR Newswire

WILMINGTON, Del., Nov. 12, 2020 /PRNewswire/ — The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company with leading market positions in Fluoroproducts, Chemical Solutions and Titanium Technologies, today announced that it has commenced a tender offer (the “Tender Offer”) to purchase for cash any and all of its outstanding 6.625% senior notes due 2023 (the “Notes”).

In connection with the Tender Offer, Chemours is also soliciting consents (the “Consents”) from holders of the Notes  (the “Consent Solicitation”) to proposed amendments to the indenture, dated as of May 12, 2015 (the “Base Indenture”), as supplemented by the first supplemental indenture, dated May 12, 2015, which governs the Notes (the “First Supplemental Indenture” and, together with the Base Indenture, as supplemented from time to time, the “Indenture”), providing for the shortening of the minimum notice periods under the Indenture for the optional redemption of the Notes by Chemours (the “Proposed Amendments”). The terms and conditions of the Tender Offer and Consent Solicitation are described in an Offer to Purchase and Consent Solicitation Statement, dated November 12, 2020 (the “Offer to Purchase and Consent Solicitation Statement”).  The following table summarizes the material pricing terms of the Tender Offer.


CUSIP / ISIN


Outstanding
Principal Amount



Title of
Notes



Early Tender
Payment(1)(2)


Tender Offer
Consideration(1)(3)


Total
Consideration (1)(3)


Registered Notes:

CUSIP: 163851AB4

ISIN: US163851AB45

 


Rule 144A Notes:

CUSIP: 163851AA6

ISIN: US163851AA61

 


Regulation S Notes:

CUSIP: U16309AA1

ISIN: USU16309AA13

$907,910,000.00

6.625% Senior

Notes due

May 15, 2023

$30.00

$987.94

$1,017.94

(1)

Per $1,000 principal amount of Notes tendered and accepted for purchase.

(2)

Included in the Total Consideration for Notes tendered and accepted for purchase on or prior to the Early Tender Deadline.

(3)

Does not include accrued and unpaid interest from the last date on which interest has been paid to, but excluding, the Early Settlement Date or the Final Settlement Date (each, as defined in the Offer to Purchase and Consent Solicitation Statement), as applicable, that will be paid on the Notes accepted for purchase.

The Tender Offer and Consent Solicitation will expire at Midnight, New York City time, at the end of December 10, 2020, unless extended or earlier terminated by Chemours (the “Expiration Date”).  No tenders submitted after the Expiration Date will be valid.  Subject to the terms and conditions of the Tender Offer, holders of Notes that are validly tendered (and not validly withdrawn) on or prior to 5:00 p.m., New York City time, on November 25, 2020 (such date and time, as it may be extended, the “Early Tender Deadline”) and accepted for purchase pursuant to the Tender Offer will be eligible to receive the Total Consideration set forth in the table above, which includes the Early Tender Payment set forth in the table above.  Holders of Notes tendering their Notes after the Early Tender Deadline and on or prior to the Expiration Date will only be eligible to receive the Tender Offer Consideration set forth in the table above, which is the Total Consideration less the Early Tender Payment.

In addition, holders of all Notes validly tendered and accepted for purchase pursuant to the Tender Offer will receive accrued and unpaid interest on such Notes from the last interest payment date with respect to such Notes to, but excluding, the Early Settlement Date or the Final Settlement Date, as applicable

The consummation of the Tender Offer and Consent Solicitation are subject to, and conditioned upon, the satisfaction or waiver of certain conditions described in the Offer to Purchase and Consent Solicitation Statement, including, among other things, Chemours consummating the New Debt Financing (as defined in the Offer to Purchase and Consent Solicitation Statement) on terms satisfactory to it, and having funds available therefrom, together with cash on hand, that will allow it to purchase the Notes pursuant to the Tender Offer.

In order for the Proposed Amendments to be adopted, Consents must be received in respect of at least a majority of the aggregate principal amount of the Notes then outstanding (excluding Notes held by Chemours or its affiliates) (the “Requisite Consents”).  Assuming receipt of the Requisite Consents, Chemours expects to execute and deliver a supplemental indenture (the “Supplemental Indenture”) to the Indenture giving effect to the Proposed Amendments, promptly following the receipt of the Requisite Consents.  The Supplemental Indenture will become effective upon execution, but will provide that the Proposed Amendments will not become operative until Chemours accepts for purchase the Notes satisfying the Requisite Consents in the Tender Offer.

Any Notes validly tendered and related Consents validly delivered may be withdrawn or revoked from the Tender Offer and the Consent Solicitation on or prior to the Early Tender Deadline.  Any Notes validly tendered and related Consents validly delivered on or prior to the Early Tender Deadline that are not validly withdrawn or validly revoked prior to the Early Tender Deadline may not be withdrawn or revoked thereafter, except as required by law.  In addition, any Notes validly tendered and related consents validly delivered after the Early Tender Deadline may not be withdrawn or revoked, except as required by law.

Concurrently with the commencement of the Tender Offer and the Consent Solicitation and conditioned upon the receipt of the net proceeds from the New Debt Financing and the lack of receipt of the Requisite Consents on or prior to the Early Tender Deadline, we issued a notice of redemption for any Notes that remain outstanding following the consummation or termination of the Offer and the Consent Solicitation.  Any such redemption would be made in accordance with the terms of the Indenture, which provides for a redemption price equal to 101.656% plus accrued and unpaid interest thereon to the redemption date. In addition, assuming the execution and delivery of the Supplemental Indenture, we currently intend, in accordance with the terms and conditions of the Indenture, as may be amended as a result of the Proposed Amendments, to mail a notice of redemption to the holders of any outstanding Notes on the Early Settlement Date, if any, although we have no legal obligation to do so and the selection of any particular redemption date is in our discretion.  These statements shall not constitute a notice of any such redemptions under the Indenture. Any such notice, if made, will only be made in accordance with the provisions of the Indenture.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any security.  No offer, solicitation, or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful.

J.P. Morgan Securities LLC is the dealer manager and solicitation agent (the “Dealer Manager”) in the Tender Offer and Consent Solicitation.  Global Bondholder Services Corporation has been retained to serve as both the depositary and the information agent (the “Depositary and Information Agent”) for the Tender Offer and Consent Solicitation.  Questions regarding the Tender Offer and Consent Solicitation should be directed to J.P. Morgan Securities LLC at (866) 834-2045 (Toll Free).  Requests for copies of the Offer to Purchase and Consent Solicitation Statement and other related materials should be directed to Global Bondholder Services Corporation at [email protected] (email), (866) 470-4200 (U.S. Toll-Free), (212) 430-3774 (Banks and Brokers) or at http://www.gbsc-usa.com/Chemours/ (website).

None of Chemours, its board of directors, the Dealer Manager, the Depositary and Information Agent, the Trustee under the Indenture, or any of Chemours’ affiliates, makes any recommendation as to whether holders of the Notes should tender any Notes in response to the Tender Offer and Consent Solicitation.  The Tender Offer and Consent Solicitation are made only by the Offer to Purchase and Consent Solicitation Statement.  The Tender Offer and Consent Solicitation are not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.  In any jurisdiction in which the Tender Offer and Consent Solicitation are required to be made by a licensed broker or dealer, the Tender Offer and Consent Solicitation will be deemed to be made on behalf of Chemours by the Dealer Manager or one or more registered brokers or dealers that are licensed under the laws of such jurisdiction.

About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in Titanium technologies, Fluoroproducts, and Chemical Solutions, providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations.  Chemours ingredients are found in plastics and coatings, refrigeration and air conditioning, mining, and general industrial manufacturing. Our flagship products include prominent brands such as Teflon™, Ti-Pure™, Krytox™, Viton™, Opteon™, Freon™ and Nafion™. In 2019, Chemours was named to Newsweek’s list of America’s Most Responsible Companies. The company has approximately 7,000 employees and 30 manufacturing sites serving approximately 3,700 customers in over 120 countries. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC.

Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words “believe,” “expect,” “will,” “anticipate,” “plan,” “estimate,” “target,” “project” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date such statements were made.

These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance, business plans, prospects, targets, goals and commitments, capital investments and projects, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, achieve anticipated synergies or cost savings, the terms and timing for completion of the Tender Offer and Consent Solicitation, including the acceptance for purchase of any Notes validly tendered and any related Consents validly delivered, the expected Early Tender Deadline, Expiration Date and Settlement Dates thereof, and the satisfaction or waiver of certain conditions of the Tender Offer and Consent Solicitation and statements regarding the terms or timing of the New Debt Financing and the redemption of the Notes, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours’ control.  Factors that may cause actual results to vary include, but are not limited to, conditions in financial markets and investor response to Chemours’ Tender Offer and Consent Solicitation and inadequate investor response on adequate terms to the New Debt Financing intended to satisfy the condition to the Tender Offer and Consent Solicitation.  In addition, the current COVID-19 pandemic has significantly impacted the national and global economy and commodity and financial markets. The full extent and impact of the pandemic is unknown and to date has included extreme volatility in financial and commodity markets, a significant slowdown in economic activity, and increased predictions of a global recession. The public and private sector response has led to significant restrictions on travel, temporary business closures, quarantines, stock market volatility, and a general reduction in consumer and commercial activity globally. Matters outside our control have affected our business and operations and may or may continue to limit travel of employees to our business units domestically and internationally, adversely affect the health and welfare of our personnel, significantly reduce the demand for our products, hinder our ability to provide goods and services to customers, cause disruptions in our supply chains, adversely affect our business partners or cause other unpredictable events.

Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020 and in our Annual Report on Form 10-K for the year ended December 31, 2019. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

CONTACT

INVESTORS

Jonathan Lock

VP, Corporate Development and Investor Relations
+1.302.773.2263
[email protected]

MEDIA

Thomas Sueta

Director, Corporate Communications
+1.302.773.3903
[email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/the-chemours-company-announces-conditional-redemption-and-cash-tender-offer-and-consent-solicitation-for-any-and-all-of-its-6-625-senior-notes-maturing-in-2023–301171890.html

SOURCE The Chemours Company

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Company nominates OPA1 as the next preclinical target for its proprietary TANGO approach to treating the underlying cause of severe genetic diseases –

OPA1 protein deficiency is the leading cause of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder –

Enrollment and dosing in Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome is ongoing; Preliminary data still anticipated in 2021 –

As of September 30, 2020, Company has $191.7 million in cash, cash equivalents and restricted cash, anticipated to fund operations into 2023 –

BEDFORD, Mass.–(BUSINESS WIRE)–
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the third quarter of 2020 and provided business updates.

“We have made important progress in recent months that includes the continued enrollment and dosing of children and adolescents in our MONARCH study, reaching agreement with the FDA to evaluate an additional higher dose of STK-001 in this study and submitting a plan to the Agency that also would allow us to evaluate multiple ascending doses. We remain on track for preliminary data from this Phase 1/2a study in 2021,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “In addition, based on new preclinical data, we are announcing today the expansion of our pipeline with the nomination of OPA1 as our next preclinical target. Consistent with our strategy, we believe our approach has the potential to be a first-in-class, disease modifying treatment for autosomal dominant optic atrophy, the most common inherited optic nerve disorder. There are currently no treatments available for this disease, which causes progressive and irreversible vision loss in both eyes starting in the first decade of life.”

The nomination of OPA1 as the Company’s next preclinical target is supported by preclinical data that demonstrated in vitro and in vivo target engagement and protein upregulation in OPA1 protein-deficient cells. In these studies, TANGO antisense oligonucleotides (ASOs) demonstrated:

  • Dose-dependent decreases in non-productive OPA1 mRNA and increases in OPA1 protein expression in vitro and in vivo.
  • An increase in OPA1 protein expression to approximately 75% of wild-type levels in an OPA1 haploinsufficient (OPA1 +/-) cell line.
  • In vivo increases in OPA1 protein levels in the retina of wild-type rabbits that correlated with increases in the level of the test ASO.
  • The test ASO was well tolerated for up to 29 days (maximum days evaluated) after intravitreal injection.

Recently completed preclinical studies have now demonstrated the ability of TANGO ASOs targeting the OPA1 gene to upregulate adenosine triphosphate production (ATP) levels in the mitochondria. These new data showed that in haploinsufficient cells where half the amount of OPA1 is present and mitochondrial function is impaired, our ASOs demonstrated an ability to increase OPA1 protein levels and also partially restore mitochondrial function as measured by an increase in ATP production. OPA1 expression is essential to retinal ganglion cell survival and visual signal transmission. Retinal ganglion cells have high energy needs making them particularly susceptible to losses in ATP production due to OPA1 haploinsufficiency.

“The ATP finding is significant because in patients with autosomal dominant optic atrophy (ADOA), the retinal ganglion cells are not producing enough ATP and have defective mitochondrial function, which leads to cell death and progressive vision loss. These new data suggest that our ASO approach can restore mitochondrial function to potentially address the underlying cause of autosomal dominant optic atrophy,” said Gene Liau Ph.D., Executive Vice President, Head of Research and Preclinical Development of Stoke Therapeutics. “Our goal is to advance an ASO that would delay, or potentially even prevent, vision loss for people living with ADOA. We aim to complete our lead optimization studies by the end of 2021 so that we can advance the most promising potential new medicine into human studies.”

OPA1 protein deficiency is the primary cause of ADOA, the most common inherited optic nerve disorder. ADOA typically presents in the first decade of life and affects approximately one in 30,000 people globally with a higher incidence in Denmark of one in 10,000 due to a founder effect. An estimated 65% to 90% of cases are caused by loss of function mutations in one allele (haploinsufficiency) in the OPA1 gene. There are over 400 different mutations reported to date in ADOA patients. Similar to Stoke’s Dravet syndrome program, Stoke’s approach for ADOA leverages upregulation of the wild-type allele and can potentially be used to treat ADOA due to loss of OPA1 activity in a mutation-independent manner.

Third Quarter 2020 Business Highlights and Recent Developments

  • On October 7, the Company announced plans to move forward with dosing of STK-001 in its ongoing Phase 1/2a MONARCH study for Dravet syndrome. The FDA will allow the Company to add an additional higher dose level to the single ascending dose portion of the study, which will now include a total of three dose levels (10 mg, 20 mg and 30 mg). In addition, the Company has submitted an amendment to the MONARCH protocol to add a multiple ascending dose portion to the study, pending FDA review.
  • On August 26, the journal Science Translation Medicine published preclinical data from studies of STK-001 that demonstrated significant improvements in survival and reductions in seizure frequency in a mouse model of Dravet syndrome.
  • On August 17, the Company appointed Gary E. Menzel, Ph.D., to both its Board of Directors and Compensation Committee. Dr. Menzel brings more than 25 years of executive management experience in the global healthcare sector and currently serves as President and Chief Executive Officer of TCR2 Therapeutics Inc.
  • On July 9, the journal Nature Communications published data that support the Company’s proprietary TANGO approach to addressing severe genetic diseases by precisely upregulating protein expression.
  • The BUTTERFLY observational study is ongoing. Despite experiencing a slowing in new patient enrollment earlier this year due to the impact of COVID-19, new patient enrollment continues, and we believe we have achieved sufficient participation in the study to provide informative data about the natural progression of Dravet syndrome.

Upcoming Anticipated Milestones

  • Preliminary safety and pharmacokinetic data from the MONARCH study are still expected in 2021.
  • Several abstracts related to Stoke’s work in Dravet syndrome have been accepted for presentation at the American Epilepsy Society (AES) Annual Meeting, December 4-8, 2020.
  • The Company expects to complete lead optimization for TANGO ASOs directed at OPA1 in 2021.

Third Quarter and Year-to-Date Results

  • Net loss for the three months ended September 30, 2020 was $13.7 million, or $0.41 per share compared to $8.6 million or $0.26 per share for the same period in 2019.
  • Research and development expenses for the three months ended September 30, 2020 were $8.1 million, compared to $6.5 million for the same period in 2019.
  • General and administrative expenses for the three months ended September 30, 2020 were $5.6 million, compared to $3.3 million for the same period in 2019.
  • Net loss for the first nine months of 2020 was $37.7 million or $1.14 per share, compared to net loss of $22.2 million or $1.71 per share for the same period in 2019.
  • Research and development expenses for the nine months ended September 30, 2020 were $23.3 million, compared to $16.7 million for the same period in 2019.
  • General and administrative expenses for the nine months ended September 30, 2020 were $15.2 million, compared to $7.9 million for the same period in 2019.
  • The increase in expenses for the three and nine month periods in 2020 over the same periods in 2019 primarily relate to increases in costs associated with personnel, third party contracts, consulting, facilities and others associated with development activities for STK-001, research on additional therapeutics and growing a public corporation.
  • As of September 30, 2020, Stoke had approximately $191.7 million in cash, cash equivalents and restricted cash, which is anticipated to fund operations into 2023.

About TANGO

TANGO (Targeted Augmentation of Nuclear Gene Output) is Stoke’s proprietary research platform. Stoke’s initial application for this technology are diseases in which one copy of a gene functions normally and the other is mutated, also called haploinsufficiencies. In these cases, the mutated gene does not produce its share of protein, so the body does not function normally. Using the TANGO approach and a deep understanding of RNA science, Stoke researchers design antisense oligonucleotides (ASOs) that bind to pre-mRNA and help the target genes produce more protein. TANGO aims to restore missing proteins by increasing – or stoking – protein output from healthy genes, thus compensating for the non-functioning copy of the gene.

About STK-001

STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in a Phase 1/2a clinical trial. Stoke believes that STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities. Stoke has generated preclinical data demonstrating proof-of-mechanism and proof-of-concept for STK-001. STK-001 has been granted orphan drug designation by the FDA as a potential new treatment for Dravet syndrome.

About Phase 1/2a Clinical Study (MONARCH)

The MONARCH study is a Phase 1/2a open-label study of children and adolescents ages 2 to 18 who have an established diagnosis of Dravet syndrome and have evidence of a pathogenic genetic mutation in the SCN1A gene. The primary objectives for the study will be to assess the safety and tolerability of STK-001, as well as to characterize human pharmacokinetics. A secondary objective will be to assess the efficacy as an adjunctive antiepileptic treatment with respect to the percentage change from baseline in convulsive seizure frequency over a 12-week treatment period. Stoke also intends to measure non-seizure aspects of the disease, such as quality of life, as secondary endpoints. Enrollment and dosing are ongoing in MONARCH and Stoke plans to enroll approximately 48 patients in the study across 20 sites in the United States. Additional information about the MONARCH study can be found at https://www.monarchstudy.com/.

About Dravet Syndrome

Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures, beginning within the first year of life. Dravet syndrome is difficult to treat and has a poor long-term prognosis. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. The effects of the disease go beyond seizures and often include severe intellectual disabilities, severe developmental disabilities, motor impairment, speech impairment, autism, behavioral difficulties and sleep abnormalities. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP. Dravet syndrome affects approximately 35,000 people in the United States, Canada, Japan, Germany, France and the United Kingdom, and it is not concentrated in a particular geographic area or ethnic group.

About Autosomal Dominant Optic Atrophy (ADOA)

Autosomal dominant optic atrophy (ADOA) is the most common inherited optic nerve disorder. It is a rare disease that causes progressive and irreversible vision loss in both eyes starting in the first decade of life. Symptoms typically begin between the ages of 4 and 6 years old, affecting males and females equally. The severity of the condition by adolescence reflects the overall level of visual function to be expected throughout most of the individual’s adult life. Roughly half of people with ADOA fail driving standards and up to 46% are registered as legally blind. ADOA is considered a haploinsufficiency, as most people living with ADOA have genetic mutations in the OPA1 gene that result in only half the necessary OPA1 protein being produced. More than 400 OPA1 mutations have been reported in people diagnosed with ADOA. Currently there is no approved treatment for people living with ADOA.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the company on Twitter at @StokeTx.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: preclinical data and study results regarding OPA1, future operating results, financial position and liquidity, the direct and indirect impact of COVID-19 on our business, financial condition and operations, including on our expenses, supply chain, strategic partners, research and development costs, clinical trials and employees; our expectation about timing and execution of anticipated milestones, responses to regulatory authorities, expected nomination of future product candidates and timing thereof, our ability to complete lead optimization of ASOs for ADOA, the timing and results of ADOA preclinical studies, our ability to develop ASOs treat the underlying causes of ADOA, our ability to advance OPA1 as our next preclinical target, and our ability to use study data to advance the development of STK-001; the ability of STK-001 to treat the underlying causes of Dravet syndrome; and the ability of TANGO to design medicines to increase protein production and the expected benefits thereof. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize STK-001, OPA1 and future product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions caused by the coronavirus pandemic; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; failure to comply with legal and regulatory requirements; risks relating to access to capital and credit markets; environmental risks; risks relating to the use of social media for our business; and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.

Financial Tables Follow

Stoke Therapeutics, Inc.

Condensed consolidated balance sheets

(in thousands, except share and per share amounts)

(unaudited)

 

 

September 30,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

191,461

 

 

$

222,471

 

Prepaid expenses and other current assets

 

 

3,615

 

 

 

3,281

 

Deferred financing costs

 

 

378

 

 

 

 

Interest receivable

 

 

2

 

 

281

 

Total current assets

 

$

195,456

 

 

$

226,033

 

Restricted cash

 

 

205

 

 

205

 

Operating lease right-of-use assets

 

 

1,381

 

 

 

 

Property and equipment, net

 

 

2,893

 

 

 

2,512

 

Total assets

 

$

199,935

 

 

$

228,750

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,095

 

 

$

751

 

Accrued and other current liabilities

 

 

5,640

 

 

 

3,350

 

Total current liabilities

 

$

6,735

 

 

$

4,101

 

Long term liabilities

 

 

665

 

 

 

221

 

Total liabilities

 

$

7,400

 

 

$

4,322

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

 

 

 

Common stock, par value of $0.0001 per share; 300,000,000 shares

authorized, 33,361,188 and 32,861,842 shares issued and outstanding as

of September 30, 2020 and December 31, 2019, respectively

 

 

3

 

 

 

3

 

Additional paid-in capital

 

 

288,249

 

 

 

282,460

 

Accumulated deficit

 

 

(95,717

)

 

 

(58,035

)

Total stockholders’ equity

 

$

192,535

 

 

$

224,428

 

Total liabilities and stockholders’ equity

 

$

199,935

 

 

$

228,750

 

Stoke Therapeutics, Inc.

Condensed consolidated statements of operations and comprehensive loss

(in thousands, except share and per share amounts)

(unaudited)

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenue

 

$

 

 

$

 

 

$

 

 

$

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

8,109

 

 

 

6,518

 

 

 

23,293

 

 

 

16,675

 

General and administrative

 

 

5,602

 

 

 

3,324

 

 

 

15,165

 

 

 

7,935

 

Total operating expenses

 

 

13,711

 

 

 

9,842

 

 

 

38,458

 

 

 

24,610

 

Loss from operations

 

 

(13,711

)

 

 

(9,842

)

 

 

(38,458

)

 

 

(24,610

)

Other income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

11

 

 

 

1,236

 

 

 

734

 

 

 

2,447

 

Other income (expense), net

 

 

16

 

 

 

2

 

 

 

42

 

 

 

(2

)

Total other income

 

 

27

 

 

 

1,238

 

 

 

776

 

 

 

2,445

 

Net loss and comprehensive loss

 

$

(13,684

)

 

$

(8,604

)

 

$

(37,682

)

 

$

(22,165

)

Net loss per share attributable to common stockholders, basic

and diluted

 

$

(0.41

)

 

$

(0.26

)

 

$

(1.14

)

 

$

(1.71

)

Weighted-average common shares outstanding, basic and diluted

 

 

33,273,597

 

 

 

32,707,647

 

 

 

32,954,727

 

 

 

12,991,672

 

 

Stoke Media & Investors

Dawn Kalmar

Vice President, Head of Corporate Affairs

[email protected]

781-303-8302

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Logo
Logo

Alithya reports second quarter revenue growth and stronger Canadian gross margins

PR Newswire

Q2-2021 Highlights

  • Revenues increased 1.5% to $68.4 million, compared to $67.4 million for the same quarter last year
  • New bookings(1) totaled $62.3 million, which translated into a book-to-bill ratio(1) of 0.91 for the quarter, and 1.03 year-to-date
  • Adjusted EBITDA(1) reached $0.8 million, a decrease from $3.2 million in the same quarter last year
  • Net loss of $5.5 million, or $0.09 per share, compared to a loss of $2.3 million, or $0.04 per share, for the same quarter last year
  • Solid financial position with net bank borrowing(1) of $15.6 million at the end of the quarter, compared to $26.9 million as at March 31, 2020
  • Renewal of the framework agreement with Desjardins Group for the provision of services and the delivery of technology projects from October 1, 2020 until 2022
  • Added twelve new clients in Q2, signed and implemented several other major Enterprise Cloud Solutions agreements, including a substantial one for the Florida Municipal Power Agency

MONTREAL, Nov. 12, 2020 /PRNewswire/ – Alithya Group inc. (TSX: ALYA) (NASDAQ: ALYA) (“Alithya” or the “Company”), a leader in strategy and digital transformation with more than 2,200 professionals and offering digital business solutions across Canada, the U.S. and Europe, reported today its results for the second quarter of fiscal 2021 ended September 30, 2020. All amounts are in Canadian dollars unless otherwise stated.

Summary of the financial results for the second quarter:


Financial Highlights

(in thousands of $, except for margin percentages)


F2021-Q2


F2020-Q2

Revenues

68,355

67,363

Gross Margin

18,732

20,683

Gross Margin (%)

27.4 %

30.7 %

Adjusted EBITDA(1)

824

3,231

Adjusted EBITDA Margin(1) (%)

1.2 %

4.8 %

Net loss

(5,491)

(2,330)


(1)

These are non-IFRS financial measures. Please refer to the “Non-IFRS Measures” section at the end of this press release and in the MD&A for more information and calculated amounts.

“We are very pleased with our results and our overall growth despite the impacts of the pandemic in certain geographies. Our revenues increased compared to the same period last year, driven by our Canadian operations and acquisitions completed last year, and partially offset by our U.S. and European operations which are still impacted by the pandemic. Compared to the first quarter, our revenues decreased as they always do in our summer quarter, but they did so to a much lesser extent than usual, which is encouraging. In addition, on a combined basis, we are pleased to report that the three acquisitions completed last year continue to generate organic growth, both year-over-year and sequentially, as well as continued superior margins,” stated Paul Raymond, President and CEO of Alithya.

“Our adjusted EBITDA and net income decreased year over year as a result of a lower utilization rate in the U.S. due to the pandemic and our strategic decision to support our employees and protect our expertise during this temporary downturn. We believe this is in the company’s best long-term interests. Conversely, our Canadian operation reported its best gross margin on record as some large clients started to ramp up and cross-selling opportunities from recent acquisitions materialize. Despite the daily challenges faced by employees in the wake of this pandemic, they continue to show passion and dedication for Alithya and its clients. I sincerely want to thank every single one of our 2,200 professionals,” continued Mr. Raymond.

“Looking forward, despite the continued uncertainty surrounding the pandemic, we are very optimistic about the second half of the year. In the third quarter, we should expect to benefit from new contracts we signed in the first half of the year and the improvement we see in the U.S. market. Furthermore, we are currently engaged in a comprehensive hiring campaign to pursue our shift to a more permanent employee base and to support our growth. Leveraging our solid financial position, which would further improve following the possible confirmation of the Paycheck Protection Program (“PPP”) loans forgiveness, in part or in full, we will continue to focus on the execution of our strategic plan which is to increase our scale through organic growth and acquisitions,” concluded Mr. Raymond.

Second Quarter Results


Revenues



Revenues amounted to $68.4 million, up 1.5%, compared to $67.4 million for the same period last year, driven by the Canadian operations. On a geographical basis, revenues in Canada increased 13.4% to $38.9 million due to the contribution from acquisitions completed last year and growth at certain key clients, partially offset by the negative impact of COVID-19. U.S. revenues decreased 9.5% to $27.1 million due primarily to the negative impact of COVID-19, partially offset by the contribution from an acquisition. Europe revenues decreased 24.3%, to $2.4 million, mainly due to the impact of COVID-19, impacting mostly one important client. On a sequential basis, our consolidated revenues decreased only 3.3%, a lesser extent than usual, for our seasonally softest quarter of the year. Assuming a constant US$ exchange rate from Q1 to Q2, the consolidated decrease would have been 1.8%. As such, by geography, revenues in Canada and Europe increased while revenues decreased in the U.S.


Gross margin


Gross margin amounted to $18.7 million, or 27.4%, a decrease compared to $20.7 million, or 30.7%, for the same quarter last year. This variation was driven primarily by reduced gross margin from Europe and the U.S. due to the negative impacts of COVID-19 on utilization rates, partially offset by increased gross margin in Canada, due to the changing mix of revenues and governmental wage subsidies. The Canadian operations, however, reported their best gross margin on record.


Adjusted EBITDA

Adjusted EBITDA amounted to $0.8 million, or an adjusted EBITDA margin of 1.2%, a decrease from $3.2 million, or an adjusted EBITDA margin of 4.8%, for the same quarter last year. The contribution from acquisitions, increased margins from higher value-added business and reduced pre-acquisition selling, general and administrative expenses, were offset by the decline in gross margin in our U.S. operations.


Net loss

Net loss amounted to $5.5 million, or $0.09 per share, compared to $2.3 million, or $0.04 per share, for the same period last year. This variation was largely due to decreased adjusted EBITDA, increased SG&A expenses, increased amortization of intangibles and depreciation, and decreased income tax recovery.


Liquidity and Capital Resources

Net cash used in operating activities amounted to $6.1 million, compared to $0.6 million for the same period last year. This variation was mainly attributable to unfavorable changes in working capital and decreased net income.

Net bank borrowing reached $15.6 million, an improvement from $26.9 million as at March 31, 2020.

Six-Month Results

Revenues were stable at $139.1 million, compared to $139.6 million last year; gross margin was $39.1 million, or 28.1%, versus $41.9 million, or 30.0% last year; adjusted EBITDA was $4.1 million, or 2.9%, compared to $6.3 million, or 4.5% last year; operating loss was $10.2 million, compared to $4.4 million last year and; net loss was $10.0 million, or $0.17 per share, compared to $3.9 million, or $0.07 per share last year, essentially for the same reasons mentioned for the second quarter.

Strategic plan

Alithya remains prudent with its outlook in the context of COVID-19 and continues to monitor the situation closely. Alithya’s priorities for the coming quarters will remain the protection of its people, its clients and the Company. Alithya is fortunate to operate as an essential services provider in a growing industry. However, the unprecedented nature of the COVID-19 crisis leads it to be very cautious and disciplined in the ongoing management of its business continuity plan.

Alithya is still focused on its 3-5-year strategic plan which sets as a goal to become a North-American digital transformation leader, with the ambition of doubling the Company’s size during this period. According to this plan, Alithya’s consolidated scale and scope should allow it to leverage its geographies, expertise, integrated offerings, and position on the value chain to target the fastest growing IT segments. In fact, Alithya’s specialization in digital technologies and the flexibility to either deploy enterprise solutions, or deliver solutions tailored to specific business objectives, responds directly to client expectations.

More specifically, the company has established a three-fold plan focusing on:

  • Increasing scale through organic growth and complementary acquisitions
  • Achieving best-in-class employee engagement
  • Providing our investors, partners and stakeholders with long-term growing return on investment

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable U.S. safe harbours (collectively “forward-looking statements”). Statements that do not exclusively relate to historical facts, as well as statements relating to management’s expectations regarding the future growth, results of operations, performance and business prospects of Alithya, and other information related to Alithya’s business strategy and future plans or which refer to the characterizations of future events or circumstances represent forward-looking statements. Such statements often contain the words “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,” “may,” “can,” “continue,” “potential,” “should,” “project,” “target,” and similar expressions and variations thereof, although not all forward-looking statements contain these identifying words.

Forward-looking statements in this press release include, among other things, information or statements about: (i) our ability to generate sufficient earnings to support our operations; (ii) our ability to take advantage of business opportunities and meet our goals set in our three to five year strategic plan; (iii) our ability to develop new business, broaden the scope of our service offerings and enter into new contracts; (iv) our strategy, future operations, and prospects; (v) our need for additional financing and our estimates regarding our future financing and capital requirements; (vi) our expectations regarding our financial performance, including our revenues, profitability, research and development, costs and expenses, gross margins, liquidity, capital resources, and capital expenditures; (vii) our ability to realize the expected synergies or cost savings relating to the integration of our business acquisitions, and (viii) the impact of the COVID-19 pandemic and related response measures on our business operations, financial results and financial position and those of our clients and on the economy in general.

Forward-looking statements are presented for the sole purpose of assisting investors and others in understanding Alithya’s objectives, strategies and business outlook as well as its anticipated operating environment and may not be appropriate for other purposes. Although management believes the expectations reflected in Alithya’s forward-looking statements were reasonable as at the date they were made, forward-looking statements are based on the opinions, assumptions and estimates of management and, as such, are subject to a variety of risks and uncertainties and other factors, many of which are beyond Alithya’s control, and which could cause actual events or results to differ materially from those expressed or implied in such statements. Such risks and uncertainties include but are not limited to those discussed in the section titled “Risks and Uncertainties” of Alithya’s Management’s Discussion and Analysis for the quarter ended September 30, 2020 and Management’s Discussion and Analysis for the year ended March 31, 2020, as well as in Alithya’s other materials made public, including documents filed with Canadian and U.S. securities regulatory authorities from time to time and which are available on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Additional risks and uncertainties not currently known to Alithya or that Alithya currently deems to be immaterial could also have a material adverse effect on its financial position, financial performance, cash flows, business or reputation.

Forward-looking statements contained in this press release are qualified by these cautionary statements and are made only as of the date of this press release. Alithya expressly disclaims any obligation to update or alter any forward-looking statements, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by applicable law. Investors are cautioned not to place undue reliance on forward-looking statements since actual results may vary materially from them.

Non-IFRS Measures

This press release includes certain measures which have not been prepared in accordance with IFRS. EBITDA, adjusted EBITDA, adjusted EBITDA margin, net bank borrowing, bookings and book-to-bill ratio are non-IFRS measures. These measures do not have any standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. These measures should be considered as supplemental in nature and not as a substitute for the related financial information prepared in accordance with IFRS. Please refer to the Management’s Discussion and Analysis for the quarter ended September 30, 2020 and the Management’s Discussion and Analysis for the year ended March 31, 2020 for a description of such measures, a reconciliation to the most directly comparable IFRS financial measure and calculated amounts.

Conference Call

Alithya will hold a conference call to discuss these results on November 12, 2020, at 9:00 AM Eastern Time. Interested parties can join the call by dialing 1-647-788-4922 (Toronto or overseas) or 1-877-223-4471 (elsewhere in North America). Persons unable to call in at this time may access a recording by calling 1-800-585-8367 and entering the passcode 9994375. This recording will be available starting November 12, 2020 as of 12:00 PM Eastern Time until 11:59 PM Eastern TimeNovember 19, 2020.

About Alithya

Alithya Group inc. is a leader in strategy and digital transformation in North America. Founded in 1992, the Company can count on more than 2,200 professionals in Canada, the U.S. and Europe. Alithya’s integrated offering is based on four pillars of expertise: strategy services, application services, enterprise cloud solutions and data and analytics. Alithya deploys solutions, services, and skillsets to craft tools tailored to its clients’ unique business needs in the financial services, manufacturing, energy, telecommunications, transportation and logistics, professional services, healthcare, and government sectors. To learn more, go to alithya.com.

Note to readers:  Management’s Discussion and Analysis and the interim condensed consolidated financial statements and notes thereto for the three months ended September 30, 2020 are available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar and on the Company’s website at www.alithya.com. Shareholders may, upon request, receive a hard copy of these documents free of charge.

Cision View original content:http://www.prnewswire.com/news-releases/alithya-reports-second-quarter-revenue-growth-and-stronger-canadian-gross-margins-301171879.html

SOURCE Alithya

S&P Global Market Intelligence and Oliver Wyman Collaborate with Citi to Support Their Commitment of a Smooth Transition to a Low-Carbon Economy

Citi to utilize the newly launched Climate Credit Analytics model suite

PR Newswire

NEW YORK, Nov. 12, 2020 /PRNewswire/ — S&P Global Market Intelligence and Oliver Wyman announced today a collaboration with Citi to support the financial institution’s commitment for a smooth transition to a low-carbon economy. Citi will be utilizing Climate Credit Analytics, a pioneering climate scenario analysis and credit analytics model suite, introduced by S&P Global Market Intelligence and Oliver Wyman at Climate Week NYC 2020.  

Climate Credit Analytics is designed to help financial institutions and corporates assess how a transition to a low-carbon economy will impact the creditworthiness of their counterparties. Its underlying insights combine S&P Global Market Intelligence’s advanced Credit Analytics risk models and unique datasets with Oliver Wyman’s industry-leading climate scenario and stress testing expertise.

“Climate Credit Analytics aligns with emerging regulatory directives and will help enable the broader industry to better analyze and manage climate risks while deploying capital to underpin long term sustainable growth. Further advancing this technology is common cause and very timely, we are delighted to be working with such capable partners,” said Colin Church, Citi’s Head of Climate Risk Management.

“This new tool will provide valuable rigor for analyzing our client portfolios under different climate transition risk scenarios, enabling us to build on our prior climate scenario analysis work. Integrating this analysis will contribute to the climate risk pillar of our Sustainable Progress Strategy and our ongoing Task Force on Climate-related Financial Disclosures (TCFD) implementation,” said Eliza Eubank, Citi’s Head of Environmental and Social Risk Management.

“Climate change is a non-traditional risk, and financial institutions and corporates are working to understand its implications. We have a deep legacy in credit analytics and we are proud to work with Citi, a leader in this area, to collaborate on creating integrated climate and credit-related analytics to navigate the effects of climate risk on the financial markets,” said Martina Cheung, S&P Global Market Intelligence’s President.

“We are delighted that Citi will be the first bank to utilize Climate Credit Analytics. This unique solution to quantify climate risks is readily customizable, incorporates the NGFS Scenarios, and covers all corporate sectors, including major greenhouse gas emitting sectors. Citi’s commitment to environmental finance exemplifies the critical role that financial institutions play in combating climate change,” said Oliver Wyman’sJohn Colas, Partner and Vice Chairman, Financial Services Americas.

 For additional information on Climate Credit Analytics, please visit S&P Global Market Intelligence.

About S&P Global Market Intelligence

At S&P Global Market Intelligence, we understand the importance of accurate, deep and insightful information. We integrate financial and industry data, research and news into tools that help track performance, generate alpha, identify investment ideas, perform valuations and assess credit risk. Investment professionals, government agencies, corporations and universities around the world use this essential intelligence to make business and financial decisions with conviction.

S&P Global Market Intelligence is a division of S&P Global (NYSE: SPGI), the world’s foremost provider of credit ratings, benchmarks and analytics in the global capital and commodity markets, offering ESG solutions, deep data and insights on critical business factors. S&P Global has been providing essential intelligence that unlocks opportunity, fosters growth and accelerates progress for more than 160 years. For more information, visit www.spglobal.com/marketintelligence.

About Oliver Wyman

Oliver Wyman is a global leader in management consulting. With offices in 60 cities across 29 countries, Oliver Wyman combines deep industry knowledge with specialized expertise in strategy, operations, risk management, and organization transformation. The firm has more than 5,000 professionals around the world who work with clients to optimize their business, improve their operations and risk profile, and accelerate their organizational performance to seize the most attractive opportunities.

Oliver Wyman is a business of Marsh & McLennan Companies [NYSE: MMC]. For more information, visit oliverwyman.com. Follow Oliver Wyman on Twitter @OliverWyman.

Media Contacts

Amanda Oey

S&P Global Market Intelligence
P. +1 (212) 438-1904
E. [email protected]

Francine Minadeo

Oliver Wyman

P. +1 (212) 345-6417
E. [email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/sp-global-market-intelligence-and-oliver-wyman-collaborate-with-citi-to-support-their-commitment-of-a-smooth-transition-to-a-low-carbon-economy-301171759.html

SOURCE S&P Global Market Intelligence

Great Bear Reports 97% Gold Recoveries from Preliminary Hinge Zone Metallurgical Tests

PR Newswire

TSX-V: GBR

VANCOUVER, BC, Nov. 12, 2020 /PRNewswire/ – Great Bear Resources Ltd. (the “Company” or “Great Bear”) (TSXV: GBR) (OTCQX: GTBAF) today reported the first gold recovery test results from its 100% owned flagship Dixie Project, in the Red Lake district of Ontario.

Chris Taylor, President and CEO of Great Bear said, “The first results from a preliminary suite of metallurgical tests planned for the various mineralized zones at Dixie have returned very high gold recoveries. Hinge zone high-grade gold samples averaging approximately 13 g/t gold recovered between 95% – 97 % of the head grade gold from conventional cyanidation bottle roll leach tests. Results in this range had been expected, as free gold dominates the Hinge zone and all other zones at Dixie, and high gold recoveries are typical of such systems. We will periodically release gold recovery results from representative samples originating from all of our gold zones over the coming months.”

Details of Hinge Zone Gold Recovery Results

  • A composite sample of 18.0 kilograms representing 10.9 metres (core length) of drill core was selected for processing from the Hinge zone.
  • Two approximately one-kilogram representative samples of Hinge zone gold mineralization collectively averaging 13.07 g/t gold head grade were analyzed at Blue Coast Research Ltd. of Parksville, British Columbia.
  • Samples were processed through a standard 48-hour bottle roll procedure at 40% solids, using a 1.0 g/L sodium cyanide solution.
  • Two primary grind samples: 1) 80% passing (“p80”) 112 µm, and 2) p80 74 µm returned 95.4% and 97.2% gold recoveries, respectively. Table 1 and Figure 1.
  • The high reported gold recoveries are similar to those reported from other mines in the Red Lake area.
  • Additional metallurgical test work consisting of sodium cyanide bottle roll tests on samples from the Hinge, Limb and LP Fault zones on the Dixie Project are currently underway. The Company will also begin gravity circuit recovery tests in 2021.

Table
1
: Gold recoveries from the first sodium cyanide leach tests of Hinge zone material.


Sample


NaCN Concentration (g/L)


% Solids


Primary Grind (p80, µm)


48 hr Au Recovery (%)


Residue Grade (Au, g/t)


Calculated Head Grade (Au, g/t)

CN-1

1.0

40

112

95.4

0.64

13.96

CN-2

1.0

40

74

97.2

0.39

13.94

About the Dixie Project

The Dixie Project is 100% owned, comprised of 9,140 hectares of contiguous claims that extend over 22 kilometres, and is located approximately 25 kilometres southeast of the town of Red Lake, Ontario. The project is accessible year-round via a 15 minute drive on a paved highway which runs the length of the northern claim boundary and a network of well-maintained logging roads.

The Dixie Project hosts two principal styles of gold mineralization:

  • High-grade gold in quartz veins and silica-sulphide replacement zones (Dixie Limb, Hinge and Arrow zones). Hosted by mafic volcanic rocks and localized near regional-scale D2 fold axes. These mineralization styles are also typical of the significant mined deposits of the Red Lake district.

  • High-grade disseminated gold with broad moderate to lower grade envelopes (LP Fault). The LP Fault is a significant gold-hosting structure which has been seismically imaged to extend to 14 kilometres depth (Zeng and Calvert, 2006), and has been interpreted by Great Bear to have up to 18 kilometres of strike length on the Dixie property. High-grade gold mineralization is controlled by structural and geological contacts, and moderate to lower-grade disseminated gold surrounds and flanks the high-grade intervals. The dominant gold-hosting stratigraphy consists of felsic sediments and volcanic units.

About Great Bear

Great Bear Resources Ltd. is a well-financed gold exploration company managed by a team with a track record of success in mineral exploration. Great Bear is focused in the prolific Red Lake gold district in northwest Ontario, where the company controls over 300 km2 of highly prospective tenure across 4 projects: the flagship Dixie Project  (100% owned), the Pakwash Property (earning a 100% interest), the Dedee Property (earning a 100% interest), and the Sobel Property (earning a 100% interest), all of which are accessible year-round through existing roads.

QA/QC and Core Sampling Protocols

Drill core is logged and sampled in a secure core storage facility located in Red Lake Ontario. Core samples from the program are cut in half, using a diamond cutting saw, and are sent to Activation Laboratories in Ontario, an accredited mineral analysis laboratory, for analysis. All samples are analysed for gold using standard Fire Assay-AA techniques. Samples returning over 10.0 g/t gold are analysed utilizing standard Fire Assay-Gravimetric methods. Pulps from approximately 5% of the gold mineralized samples are submitted for check analysis to a second lab. Selected samples are also chosen for duplicate assay from the coarse reject of the original sample. Selected samples with visible gold are also analyzed with a standard 1 kg metallic screen fire assay. Certified gold reference standards, blanks and field duplicates are routinely inserted into the sample stream, as part of Great Bear’s quality control/quality assurance program (QAQC). No QAQC issues were noted with the results reported herein.

Qualified Person and NI 43-101 Disclosure

Results for the metallurgical test program were provided and approved by Andrew Kelly, P.Eng., of Blue Coast Research Ltd., a Qualified Person for the purpose of National Instrument 43-101.

Mr. R. Bob Singh, P.Geo, Director and VP Exploration, and Ms. Andrea Diakow P.Geo, Exploration Manager for Great Bear are the Qualified Persons as defined by National Instrument 43-101 responsible for the accuracy of technical information contained in this news release.

ON BEHALF OF THE BOARD


“Chris Taylor”                                  

Chris Taylor, President and CEO


Cautionary note regarding forward-looking statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes.

Forward-looking information are based on management of the parties’ reasonable assumptions, estimates, expectations, analyses and opinions, which are based on such management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect.

Such factors, among other things, include: impacts arising from the global disruption caused by the Covid-19 coronavirus outbreak, business integration risks; fluctuations in general macroeconomic conditions; fluctuations in securities markets; fluctuations in spot and forward prices of gold or certain other commodities; change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations pressures, cave-ins and flooding); discrepancies between actual and estimated metallurgical recoveries; inability to obtain adequate insurance to cover risks and hazards; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties.

Great Bear undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/great-bear-reports-97-gold-recoveries-from-preliminary-hinge-zone-metallurgical-tests-301171776.html

SOURCE Great Bear Resources Ltd.